Richter’s Bold Strategy to Maintain Global Leadership in Pharma and Biotech
Richter Pharmaceuticals, a Hungarian company known for its innovative medicines, has unveiled a new long-term strategy aimed at doubling its revenue by 2035. The strategy, known as Richter 2035, was approved by the board of directors and sets ambitious goals for the company’s growth over the next decade and beyond.
CEO Gábor Orbán shared that the strategy includes plans for the company’s non-CNS revenues to increase by 7-8% each year, reaching a target of EUR 3.2-3.5 billion by 2035. This growth will be driven by investments in research and development, as well as the introduction of new and innovative products.
One key focus of the strategy is on women’s healthcare, with the aim of doubling revenue and R+D investments in this division. Péter Turek, head of the women’s healthcare division, emphasized the importance of maximizing Richter’s current portfolio and introducing new products to drive growth in this area.
In the neuropsychiatry division, leader Kristóf Kóczián highlighted the value of Richter’s key product, cariprazine, and the company’s plans to maximize its value until the patent expires in 2029. Additionally, Richter aims to address the unmet needs in mental health treatment and continue to innovate in this area.
Richter also has plans to double revenue from generic medicines, increase profitability, and expand its biotechnology division. The company aims to achieve over 20% clean EBIT margin and increase R+D spending to 7% of revenue in the coming years.
Overall, Richter is optimistic about its financial outlook and plans to pay out dividends to investors based on its adjusted net income. The company expects continued growth and success in the pharmaceutical industry, with plans to continue innovating and introducing new products to market.
Investors and stakeholders are eager to see how Richter’s new strategy will unfold and the impact it will have on the company’s growth and success in the years to come.
